← All articles

Growth · 9 min read · 2026-10-27

How Long Should Your SaaS Free Trial Be? (Measured)

Most SaaS teams choose a trial length the same way: someone says "let's do 14 days," someone else counters with 30, and whoever is more senior wins. The decision then calcifies and never gets revisited, even though it quietly shapes the sales cycle, the onboarding pressure, and the conversion rate. It does not have to be a guess. The timing of when trial users actually convert is sitting in your data, and plotting it answers the length question empirically — including the uncomfortable finding that a longer trial often buys you nothing but a longer wait for the same customers.

This is a worked example: how to build a cumulative conversion-timing curve from a trial cohort, where to read the optimal length off it, and the one statistical trap — cohort truncation — that ruins the analysis if you ignore it. It sits alongside the benchmark-focused free-to-paid conversion benchmarks guide, but where that post gives you reference numbers, this one shows you how to derive a decision from your own.

The question is about timing, not just rate

The trial-length decision is really a question about whenconversions happen, not just how many. Imagine two trials of the same product: if 90% of the customers who will ever convert do so within the first ten days, a 30-day trial is mostly dead air — three extra weeks that add almost no conversions while delaying every customer's start and lengthening your cash cycle. If instead conversions keep accruing steadily through day 25, a 14-day trial is cutting people off before they decide. You cannot tell which world you live in from the final conversion rate alone; you have to look at the shape of conversion over time.

That shape is a cumulative curve: the running share of a trial cohort that has converted, plotted against days since trial start. It rises fast at first — the eager, high-intent users — then bends and flattens as the stragglers trickle in. The flattening point is the empirical signal you are after: beyond it, each additional day of trial buys steadily less. Reading length off that bend turns a debate into a measurement, and it is the same time-to-value thinking formalized in the time-to-value percentile guide, applied to conversion instead of activation.

A worked example from real cohort data

A well-known cohort analysis of trial data makes the pattern concrete. It compared a freemium plan, a 14-day trial, and a 30-day trial, and found that the 14-day trial converted faster than the 30-day trial, but the curves converge once about 80% of customers convert, around 40 days after the trial starts. Read that carefully: the shorter trial did not win more customers in the end — it compressed the same conversions into a tighter window. The two curves meeting by day 40 is the empirical case against assuming a longer trial lifts conversion; mostly it just spreads the identical conversions over more calendar time.

The same analysis surfaced a second finding that reshapes the whole question: roughly half of SaaS conversions happen after the trial ends. Users come back days or weeks later — a sales follow-up, an expired-trial email, their own budgeting timing — and convert then. That means the trial window is not a wall; shortening it does not necessarily lose the slow deciders, it moves them from "converted in trial" to "converted after trial," which is a large part of why the final rate holds steady across lengths. It also means any measurement that counts only in-trial conversions badly undercounts the truth, a line-drawing problem related to the one in the open vs closed conversion-window guide.

Cohort truncation: the trap that ruins the curve

The one mistake that invalidates this whole analysis is including cohorts too recent to have finished converting. If a user started a trial five days ago, they can only possibly appear in the first five days of your timing curve — so including them drags down every later point and makes the curve flatten earlier than it really does. Do this across a mix of recent and old cohorts and you will "discover" an optimal trial length that is really just an artifact of your data cutoff, and you will shorten the trial based on a measurement error.

The fix is to truncate the cohort: only include trial starters old enough that the full conversion window has already elapsed for all of them. Given that conversions accrue out to roughly day 40–60 in the data above, that usually means analyzing only cohorts that began at least 60 days ago, and measuring days-to-convert within that closed set. This right-censoring discipline is the same incomplete-window hazard that distorts retention curves, described in the small-N retention guide: a curve built on cohorts that have not "matured" tells you about your cutoff date, not your users.

Reading the length off the curve

With a properly truncated cohort, the decision is almost mechanical. Find the point where the cumulative conversion curve flattens — a common rule is where it reaches 80–90% of eventual conversions — and that elapsed time is your candidate trial length, because days beyond it add conversions too slowly to justify the delay they impose on everyone else. If your curve hits 85% by day 12, a 14-day trial is well matched and a 30-day trial is mostly waiting. If it is still climbing at day 25, a 14-day trial is leaving conversions on the table and you should lengthen it or add an extension offer.

Two refinements keep this honest. First, decide deliberately how to treat post-trial conversions: since half may land after the window, define whether your "length" optimizes in-trial conversion speed or total conversion, and measure accordingly — they can point to different lengths. Second, do not standardize before checking segments. Time-to-value differs sharply between a self-serve SMB and a multi-stakeholder enterprise deal, so build the curve per segment; if they flatten at different points, a segment-specific length beats a single global one. The segmentation logic is the same as in the trial-benchmark-by-type guide. Pick the length from your own flattening point, revisit it when the product or audience changes, and the 14-versus-30 debate stops being an opinion.

FAQ

How do I measure the right free-trial length from my own data?

Build a conversion-timing curve from a cohort of trial starters: for a group of users who all started a trial at least ~60 days ago, plot the cumulative share who have converted to paid against days-since-trial-start. The curve rises steeply at first, then flattens. The point where it flattens — where extra days stop buying meaningfully more conversions — is your empirical trial length. Critically, you must use a cohort old enough that everyone has had the full window to convert (that is the cohort-truncation point), otherwise recent, still-converting users bias the curve downward and make the trial look less effective than it is. Read the length off the flattening point, not off a convention.

Is a 14-day or 30-day trial better?

The evidence says the difference shows up mainly in conversion speed, not final conversion rate — the two curves tend to converge. A cohort analysis of trial data found a 14-day trial converted faster than a 30-day trial, but the curves came together by around day 40, where roughly 80% of eventual conversions had happened. So a 14-day trial does not usually win more customers; it compresses the same conversions into a shorter window, which is still valuable because it shortens your sales cycle and feedback loop. The real answer is product-specific: a simple product whose aha moment lands in a day or two is well served by a short trial, while a complex B2B product that genuinely needs weeks to evaluate is not — which is exactly why you measure your own timing curve instead of copying a number.

Why does cohort truncation matter when measuring trial conversion?

Because conversions keep arriving for weeks, and a cohort that is too recent hasn't had time to finish converting — so its curve understates the true conversion rate and its flattening point is an artifact of the data cutoff, not of user behavior. If you include users who started a trial five days ago in a 'days to convert' analysis, they can only contribute to the first five days of the curve and pull the later points down. The fix is to only include cohorts that started long enough ago that the full conversion window has elapsed (often 40–60 days for SaaS), which is called right-censoring or truncating the cohort. It is the same hazard that biases any incomplete-window retention or funnel measurement.

Doesn't a lot of trial conversion happen after the trial ends?

Yes, and that is one of the most useful and overlooked findings. A cohort analysis reported that roughly half of SaaS conversions happen after the trial ends — users come back and buy days or weeks later, through a sales follow-up, an expired-trial email, or their own timing. This has two consequences for measurement. First, if you only count conversions that occur during the trial window, you undercount your true conversion rate by a large margin. Second, the 'trial length' decision is partly a decision about where to draw the line between in-trial and post-trial conversion — shortening the trial does not necessarily lose those late converters, it just moves them from 'in trial' to 'post trial,' which is why the final conversion rate often holds steady.

Should trial length be the same for every segment?

Not necessarily. Time-to-value varies by segment — a self-serve SMB user and a multi-stakeholder enterprise account reach their aha moment on very different timelines — so the flattening point of the conversion-timing curve can differ by segment, and a single global trial length will be too short for one and too long for another. Build the timing curve separately for your main segments (by plan, company size, or acquisition source) before standardizing. If the curves flatten at clearly different points, a segment-specific trial length or an extension offer for the slower segment will convert better than one length imposed on everyone.